key: cord-0873902-s2ffnge8
authors: Adiletta, Girolamo; Baglioni, Stefano; Bettoncelli, Germano; Bracciale, Pierluigi; Cazzola, Mario; Clini, Enrico M.; Cutrera, Renato; D’Adduzio, Franco; de Blasio, Francesco; Ferraro, Fausto; Fumagalli, Roberto; Lequaglie, Cosimo; Matera, Maria Gabriella; Numis, Fabio; Palange, Paolo; Picciolo, Stefano; Potena, Alfredo; Romano, Francesco; Sabato, Eugenio; Sacchetta, Antonio; Spatafora, Mario; Stefanelli, Francesco; Zottola, Carlo
title: Comments on “Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations” by D’Amato et al.
date: 2021-04-08
journal: Multidiscip Respir Med
DOI: 10.4081/mrm.2021.757
sha: aaf43a6cd0a0696fd5e64853f7a4f9d228afcb6c
doc_id: 873902
cord_uid: s2ffnge8

nan

We have read with interest the letter from D'Amato et al. entitled "Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations" [1] , that aimed to demonstrate the usefulness of early use of prednisone and low molecular weight heparin (LMWH), in all patients with domiciliary SARS-CoV-2 infection, as a therapeutic strategy to reduce the risk of hospital admission. We are honestly surprised to read in your journal that you have accepted for publication such findings from a study that uses a therapeutic strategy which has not been approved by regulatory organisms and reports no evidence of approval from any local Ethical Committee. Indeed, these data refer to quarantined patients with mild symptoms with no indication to hospital admission by definition. To be more specific, none of the patients received neither physical medical examination, nor underwent any radiological confirmation of a possible disease progression with lung involvement. Finally, methodological weakness in study design (lack of control group with patients treated with symptomatic drugs only) precludes any firm conclusion among that we have read through the manuscript.

The letter content was echoed by a regional newspaper [2] and, as expected, immediately raised confusion and misunderstanding in the general public, mainly deriving from the discrepancies between what authors stated and what the medical communities advise nationwide. In fact, medical community (General Practitioners and even more specialists) are all following statements/guidelines that suggest the use of steroids only in patients with evidence of pneumonia with respiratory insufficiency [3] [4] [5] [6] [7] , and LMWH in bed-bound patients with significant cardiovascular and metabolic comorbidities [8] [9] [10] [11] [12] .

This also implicitly asserts the absolute need of a careful objective clinical evaluation to prevent any potentially dangerous misuse or overuse of medications.

We believe that in the pandemic era with several sources with misleading information, a scientific journal should not agree in helping confusion.

We hope that authors would be able to specify their beliefs to eventually favor a better understanding by the non-specialized press and social media.

Preventive home therapy for symptomatic patients affected by COVID-19 and followed by teleconsultations

svolta con la terapia napoletana: «Medicinali subito e nessun decesso

Dexamethasone in hospitalized patients with Covid-19 -Preliminary report

The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis

Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis

Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study

Dexamethasone for COVID-19? Not so fast

Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19

Online Ahead of Print. 10. National Institutes of Health. COVID-19 Treatment Guidelines. Antithrombotic Therapy in Patients with COVID-19. Last Updated

COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review

Low molecular weight heparins in the treatment of adult patients with COVID-19